Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

$MRSN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MRSN alert in real time by email
SC 13G/A 1 d901805dsc13ga.htm SC 13G/A SC 13G/A

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

Mersana Therapeutics Inc

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

59045L106

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)

 

Rule 13d-1(c)

 

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No. 59045L106

 

 1   

 NAMES OF REPORTING PERSONS

 

 Balyasny Asset Management L.P.

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5    

 SOLE VOTING POWER

 

 535,819 (See Item 4)

   6   

 SHARED VOTING POWER

 

 None

   7   

 SOLE DISPOSITIVE POWER

 

 535,819 (See Item 4)

   8   

 SHARED DISPOSITIVE POWER

 

 None

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 535,819 (See Item 4)

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 ☐

 

 Not Applicable

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 0.44%

12  

 TYPE OF REPORTING PERSON*

 

 IA, PN

 

 

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 59045L106

 

 1   

 NAMES OF REPORTING PERSONS

 

 BAM GP LLC

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5    

 SOLE VOTING POWER

 

 535,819 (See Item 4)

   6   

 SHARED VOTING POWER

 

 None

   7   

 SOLE DISPOSITIVE POWER

 

 535,819 (See Item 4)

   8   

 SHARED DISPOSITIVE POWER

 

 None

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 535,819 (See Item 4)

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 ☐

 

 Not Applicable

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 0.44%

12  

 TYPE OF REPORTING PERSON*

 

 HC, OO

 

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 59045L106

 

 1   

 NAMES OF REPORTING PERSONS

 

 Balyasny Asset Management Holdings LP

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5    

 SOLE VOTING POWER

 

 535,819 (See Item 4)

   6   

 SHARED VOTING POWER

 

 None

   7   

 SOLE DISPOSITIVE POWER

 

 535,819 (See Item 4)

   8   

 SHARED DISPOSITIVE POWER

 

 None

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 535,819 (See Item 4)

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 ☐

 

 Not Applicable

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 0.44%

12  

 TYPE OF REPORTING PERSON*

 

 HC, PN

 

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 59045L106

 

 1   

 NAMES OF REPORTING PERSONS

 

 Dames GP LLC

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 Delaware

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5    

 SOLE VOTING POWER

 

 535,819 (See Item 4)

   6   

 SHARED VOTING POWER

 

 None

   7   

 SOLE DISPOSITIVE POWER

 

 535,819 (See Item 4)

   8   

 SHARED DISPOSITIVE POWER

 

 None

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 535,819 (See Item 4)

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 ☐

 

 Not Applicable

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 0.44%

12  

 TYPE OF REPORTING PERSON*

 

 HC, OO

 

*SEE INSTRUCTIONS BEFORE FILLING OUT.


CUSIP No. 59045L106

 

 1   

 NAMES OF REPORTING PERSONS

 

 Dmitry Balyasny

 2  

 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

 (a) ☐  (b) ☐

 

 3  

 SEC USE ONLY

 

 4  

 CITIZENSHIP OR PLACE OF ORGANIZATION

 

 United States

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

   5    

 SOLE VOTING POWER

 

 535,819 (See Item 4)

   6   

 SHARED VOTING POWER

 

 None

   7   

 SOLE DISPOSITIVE POWER

 

 535,819 (See Item 4)

   8   

 SHARED DISPOSITIVE POWER

 

 None

 9   

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

 535,819 (See Item 4)

10  

 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

 

 ☐

 

 Not Applicable

11  

 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

 0.44%

12  

 TYPE OF REPORTING PERSON*

 

 HC, IN

 

 

*SEE INSTRUCTIONS BEFORE FILLING OUT.


Item 1    (a)       Name of Issuer:
         Mersana Therapeutics Inc
   (b)       Address of Issuer’s Principal Executive Offices:
         840 Memorial Drive
         Cambridge, MA 02139
Item 2    (a) – (c)       This statement is filed on behalf of the following:
      (1)    Balyasny Asset Management L.P. is a Delaware limited partnership (“BAM”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
      (2)    BAM GP LLC is a Delaware limited liability company (“BAM GP”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. BAM GP is the General Partner of BAM.
      (3)    Balyasny Asset Management Holdings LP is a Delaware limited partnership (“BAM Holdings”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. BAM Holdings is the Sole Member of BAM GP.
      (4)    Dames GP LLC is a Delaware limited liability company (“Dames”), with its principal business office at 444 West Lake Street, 50th Floor, Chicago, IL 60606. Dames is the General Partner of BAM Holdings.
      (5)    Dmitry Balyasny, a United States citizen whose business address is 444 West Lake Street, 50th Floor, Chicago, IL 60606. Dmitry Balyasny is the Managing Member of Dames.
   (d)    Title of Class of Securities:
      Common Stock, par value $0.0001 per shares (“Shares”)
   (e)    CUSIP Number:
      59045L106


Item 3         If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:
  (a)       Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
  (b)       Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
  (c)       Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
  (d)       Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
  (e)       An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
  (f)       An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
  (g)       A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
  (h)       A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
  (i)       A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
  (j)       A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
  (k)       Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

Item 4

Ownership:

BAM

 

  (a)

Amount Beneficially Owned:

By virtue of its position as the investment manager of Atlas Diversified Master Fund, Ltd. (“ADMF”), the direct holder of the 9,698,147 Shares reported herein, BAM may be deemed to exercise voting and investment power over such Shares held by ADMF and thus may be deemed to beneficially own such Shares.

 

  (b)

Percent of Class:

0.44%


  (c)

Number of Shares as to which person has:

 

  (i)

Sole power to vote or to direct vote:

535,819

 

  (ii)

Shared power to vote or to direct vote:

None

 

  (iii)

Sole power to dispose or direct disposition of:

535,819

 

  (iv)

Shared power to dispose or to direct disposition of:

None

BAM GP

 

  (b)

Amount Beneficially Owned:

By virtue of its position as the General Partner of BAM, BAM GP may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares.

 

  (b)

Percent of Class:

0.44%

 

  (c)

Number of Shares as to which person has:

 

  (i)

Sole power to vote or to direct vote:

535,819

 

  (ii)

Shared power to vote or to direct vote:

None

 

  (iii)

Sole power to dispose or direct disposition of:

535,819

 

  (iv)

Shared power to dispose or to direct disposition of:

None


BAM Holdings

 

  (c)

Amount Beneficially Owned:

By virtue of its position as the Sole Member of BAM GP, BAM Holdings may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares.

 

  (b)

Percent of Class:

0.44%

 

  (c)

Number of Shares as to which person has:

 

  (i)

Sole power to vote or to direct vote:

535,819

 

  (ii)

Shared power to vote or to direct vote:

None

 

  (iii)

Sole power to dispose or direct disposition of:

535,819

 

  (iv)

Shared power to dispose or to direct disposition of:

None

Dames

 

  (d)

Amount Beneficially Owned:

By virtue of its position as the General Partner of BAM Holdings, Dames may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares.

 

  (b)

Percent of Class:

0.44%


  (c)

Number of Shares as to which person has:

 

  (i)

Sole power to vote or to direct vote:

535,819

 

  (ii)

Shared power to vote or to direct vote:

None

 

  (iii)

Sole power to dispose or direct disposition of:

535,819

 

  (iv)

Shared power to dispose or to direct disposition of:

None

Dmitry Balyasny

 

  (a)

Amount Beneficially Owned:

By virtue of his position as the Managing Member of Dames, Mr. Balyasny may be deemed to exercise voting and investment power over the Shares held directly by ADMF and thus may be deemed to beneficially own such Shares.

 

  (b)

Percent of Class:

0.44%

 

  (c)

Number of Shares as to which person has:

 

  (i)

Sole power to vote or to direct vote:

535,819

 

  (ii)

Shared power to vote or to direct vote:

None

 

  (iii)

Sole power to dispose or direct disposition of:

535,819

 

  (iv)

Shared power to dispose or to direct disposition of:

None


Item 5

Ownership of Five Percent or Less of a Class:

Not Applicable

 

Item 6

Ownership of More than Five Percent on Behalf of Another Person:

ADMF, a Cayman Islands exempted company that is an investment management client of BAM, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

 

Item 7

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable

 

Item 8

Identification and Classification of Members of the Group:

Not Applicable

 

Item 9

Notice of Dissolution of Group:

Not Applicable

 

Item 10

Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 6, 2024

 

BALYASNY ASSET MANAGEMENT L.P.
By:  

/s/ Scott Schroeder

Name:   Scott Schroeder
Title:   Authorized Signatory
BAM GP LLC
By:  

/s/ Scott Schroeder

Name:   Scott Schroeder
Title:   Authorized Signatory
BALYASNY ASSET MANAGEMENT HOLDING LP
By:  

/s/ Scott Schroeder

Name:   Scott Schroeder
Title:   Authorized Signatory
DAMES GP LLC
By:  

/s/ Scott Schroeder

Name:   Scott Schroeder
Title:   Authorized Signatory
DMITRY BALYASNY
By:  

/s/ Dmitry Balyasny

 

Get the next $MRSN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRSN

DatePrice TargetRatingAnalyst
2/6/2025Outperform
William Blair
11/15/2024$5.00Buy
Citigroup
3/19/2024$5.00Underweight → Neutral
JP Morgan
2/29/2024$6.00Neutral → Buy
BTIG Research
2/29/2024$7.00Neutral → Buy
Guggenheim
2/29/2024$2.00 → $7.00Neutral → Outperform
Wedbush
12/4/2023$1.00 → $5.00Neutral → Buy
Citigroup
7/28/2023$7.00 → $1.00Outperform → Neutral
Robert W. Baird
More analyst ratings

$MRSN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., April 04, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on April 1, 2025, an authorized sub-committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 26,790 shares of its common stock, to one new employee whose employment commenced in March 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Lis

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

    CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Phase 1 dose escalation and backfill cohort clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) will be presented in an oral session at the ESMO Breast Cancer 2025 Annual Congress, which is being held from May 14-17, 2025, in Munich, Germany. Oral Presentation Details Title: Clinical Activity of Emiltatug Ledadotin (Emi-Le), a B7-H4-Directed ADC, in Patients with TNBC who Received at Least

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

    Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously treated with at least one topoisomerase-1 inhibitor (topo-1) ADCPlan to present additional clinical data from dose escalation and backfill cohorts in 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business upda

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRSN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MRSN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MRSN
SEC Filings

See more

$MRSN
Leadership Updates

Live Leadership Updates

See more
  • Mersana Therapeutics Announces Changes in Leadership

    Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mersana Therapeutics Provides Statement About SVB

    CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

    CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRSN
Financials

Live finance-specific insights

See more
  • Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

    Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-negative breast cancer (TNBC) previously treated with at least one topoisomerase-1 inhibitor (topo-1) ADCPlan to present additional clinical data from dose escalation and backfill cohorts in 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business upda

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

    CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning. To access the call, please dial 833-255-2826 (domestic) or 412-317-0689 (international). A live webcast of the presentation will be available on the Invest

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

    CAMBRIDGE, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the U.S. Food and Drug Administration (FDA) recently granted an additional Fast Track designation to XMT-1660. The company also announced that the World Health Organization has approved emiltatug ledadotin (abbreviated as Emi-Le) as XMT-1660's international nonproprietary name (INN). The new Fast Track designation is for the treatment of advanced or metastatic breast cancer in patients with human epide

    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MRSN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more